Multiple Myeloma

Publication Date: April 1, 2019

Key Points

Key Points

In 2018, an estimated 30,770 new cases of multiple myeloma will be diagnosed in the United States, representing 1.8% of all new cancer cases.

The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.

Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.

The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.

Treatment

Treatm...

...nsplant Eligible...

...should be referred to a transplant center to det...

...logic age and renal function should not be...

...imal regimen and number of cycles rem...

...front transplant should be offered...

...d with stem cell toxicity, such as...

...ell collection (sufficient for more...

...nimal response required to proceed to SCT is not...

...ose melphalan is the recommended con...

...utologous SCT should not be routinely...

...age or delayed SCT may be used as consolidation...

...neic transplant for multiple myeloma is not...

...therapy is not routinely recommen...

...domide maintenance therapy should b...

...ntolerant of or unable to receive lenalidomide, bo...

...tients, maintenance therapy with a prote...

...ficient evidence to make modifications...

The quality and depth of response...

...of initial therapy for transplant eligible pati...

...nded that depth of response be assessed with...

...body low dose CT scan has been shown...


...lant Ineligible...

...reatment recommendations for patients with...

...atment for patients with multiple myeloma who...

...herapies for patients with multiple mye...

...nts should balance the potential improvement i...

...nuous therapy should be offered ove...

...al of initial therapy for transplant ine...

...of response for all patients should...

...icient evidence to support change in type...

...on of therapy, one should define patient s...

...recommended that patients be monitore...


...elapsed Diseas...

...tment for biochemically relapsed myeloma should...

...relapsed patients with symptoms due to mye...

...should be administered on first relapse, tho...

...t of relapsed multiple myeloma may be cont...

...apies should be taken into consideration whe...

Autologous stem cell transplantation,...

...isk status of the patients should b...

...assessment at the time of relapse shoul...

...ssment of other risk factors such as ren...

...ith genetic high-risk disease a triplet combinat...

...with renal insufficiency, drugs shoul...

In patients with plasma cell leukemia or extra me...

...revised response criteria should be used for respo...

...able parameters need to be followed includi...

...xcluding marrow and imaging should be c...

...ponse assessment should be performed after one c...


Figure 1. Algorithm On Management of P...


...e 1. Drugs Used in the Management of P...


...le 2. Diagnostic Criteria for Acti...


Table 3. Revised International Staging S...


...parison of Select Risk Prediction Mo...


...IMWG Response CriteriaHaving trouble...


...Estimated Cost of Drugs for Multip...